Literature DB >> 8426037

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study.

J E Morley1, H M Perry, F E Kaiser, D Kraenzle, J Jensen, K Houston, M Mattammal, H M Perry.   

Abstract

OBJECTIVE: To examine the effects of testosterone administration to older hypogonadal males (bioavailable testosterone less than 70 ng/dL).
DESIGN: Alternate-case controlled trial.
SETTING: St. Louis University. PATIENTS: Eight males (mean age 77.6 +/- 2.3 years) who received testosterone and six males (mean age 76 +/- 2.3 years) who served as controls. Selected from alumni of the SHEP trial and attendees at the St. Louis University Impotence Clinic.
INTERVENTIONS: Testosterone enanthate (200 mg/mL) was administered intramuscularly to the treatment group every 2 weeks for 3 months. MEASUREMENTS: Serum testosterone, bioavailable testosterone and estradiol, weight, % body fat, right hand muscle strength, balance, cholesterol, HDL-cholesterol, hematocrit, BUN, creatinine, albumin, calcium, PTH, 25(OH) vitamin D, 1,25(OH)2 vitamin D, osteocalcin, prostate-specific antigen, and fructosamine.
RESULTS: Males who received testosterone had a significant increase in testosterone and bioavailable testosterone concentration, hematocrit, right hand muscle strength and osteocalcin concentration. They had a decrease in cholesterol (without a change in HDL-cholesterol) levels and decreased BUN/Creatinine ratios.
CONCLUSION: These preliminary findings support the need for long term studies of testosterone therapy in older hypogonadal males.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426037     DOI: 10.1111/j.1532-5415.1993.tb02049.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  65 in total

Review 1.  [Pathophysiology of catabolism in undernurished elderly patients].

Authors:  D Baez-Franceschi; J E Morley
Journal:  Z Gerontol Geriatr       Date:  1999-07       Impact factor: 1.281

Review 2.  Osteoporosis in men: are we ready to diagnose and treat?

Authors:  H M Perry; J E Morley
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 3.  Andropause: to treat or not to treat?

Authors:  S Basaria; A Dobs
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 4.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 5.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

6.  Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.

Authors:  Anne M Kenny; Alison Kleppinger; Kristen Annis; Margaret Rathier; Bruce Browner; James O Judge; Daniel McGee
Journal:  J Am Geriatr Soc       Date:  2010-06       Impact factor: 5.562

Review 7.  Intramuscular Anabolic Signaling and Endocrine Response Following Resistance Exercise: Implications for Muscle Hypertrophy.

Authors:  Adam M Gonzalez; Jay R Hoffman; Jeffrey R Stout; David H Fukuda; Darryn S Willoughby
Journal:  Sports Med       Date:  2016-05       Impact factor: 11.136

Review 8.  Male osteoporosis: new trends in diagnosis and therapy.

Authors:  Hosam K Kamel
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 9.  Osteoporosis in men.

Authors:  Sundeep Khosla; Shreyasee Amin; Eric Orwoll
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

10.  Effects of testosterone therapy on muscle performance and physical function in older men with mobility limitations (The TOM Trial): design and methods.

Authors:  Nathan K LeBrasseur; Newsha Lajevardi; Renee Miciek; Norman Mazer; Thomas W Storer; Shalender Bhasin
Journal:  Contemp Clin Trials       Date:  2008-10-29       Impact factor: 2.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.